Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Taisei Hokan Imperial Rescript on Education Imperial Rescript to Soldiers and Sailors Japanese Taiwan Japanese Korea Japanese nationalism List of political figures of Meiji Japan Meiji Memorial Picture Gallery Rising Sun Flag High Treason Incident Battle of Pyongyang (1894) Battle of Yalu River (1894) Battle of Jiuliancheng 1874 Japanese expedition to Taiwan Japanese invasion of Taiwan (1895) Ryukyu Disposition Shrine Consolidation Policy
vg: vestigial – A spontaneous mutation, discovered in 1919 by Thomas Morgan and Calvin Bridges. Vestigial wings are those not fully developed and that have lost function. Since the discovery of the vestigial gene in Drosophila melanogaster, there have been many discoveries of the vestigial gene in other vertebrates and their functions within the vertebrates. The vestigial gene is considered to be one of the most important genes for wing formation, but when it becomes over expressed the issue of ectopic wings begin to form. The vestigial gene acts to regulate the expression of the wing imaginal discs in the embryo and acts with other genes to regulate the development of the wings. A mutated vestigial allele removes an essential sequence of the DNA required for correct development of the wings. w: white – Drosophila melanogaster wild type typically expresses a brick-red eye color. The white eye mutation in fruit flies is caused due to the absence of two pigments associated with red and brown eye colors; peridines (red) and ommochromes (brown). In January 1910, Thomas Hunt Morgan first discovered the white gene and denoted it as w. The discovery of the white-eye mutation by Morgan brought about the beginnings of genetic experimentation and analysis of Drosophila melanogaster. Hunt eventually discovered that the gene followed a similar pattern of inheritance related to the meiotic segregation of the X chromosome. He discovered that the gene was located on the X chromosome with this information.
Both the pharmaceutical supply chain and the illicit supply chain obtain cocaine from coca cultivated in Latin America, but they operate under very different controls and oversight. In Peru, for example, legal coca cultivation is monopolized by the state company National Coca Company (ENACO), yet approximately 90% of coca leaves produced in the country are diverted to illegal actors for cocaine manufacturing. As a result, these illicit coca crops are a primary target of ongoing government-led coca eradication efforts. Cocaine is prohibited in competition for athletes by the World Anti-Doping Agency (WADA), which lists it as a stimulant on its International Standard for the Prohibited List.
Sources: en.wikipedia.org
Efficacy was evaluated in KEYNOTE-590 (NCT03189719), a multicenter, randomized, placebo-controlled trial that enrolled 749 participants with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma who were not candidates for surgical resection or definitive chemoradiation. In May 2021, the US FDA approved pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of people with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Approval was based on the prespecified interim analysis of the first 264 participants of the ongoing KEYNOTE-811 (NCT03615326) trial, a multicenter, randomized, double‑blind, placebo‑controlled trial in participants with HER2‑positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who had not previously received systemic therapy for metastatic disease. In July 2021, the US FDA approved pembrolizumab for high-risk, early-stage, triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. The FDA also granted regular approval to pembrolizumab in combination with chemotherapy for people with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥ 10) as determined by an FDA-approved test.
It is responsible for the decarboxylation of α-keto acids formed by the transamination of valine, leucine, and isoleucine and produces the primers used for branched-chain fatty acid synthesis. The activity of this enzyme is much higher with branched-chain α-keto acid substrates than with straight-chain substrates, and in Bacillus species its specificity is highest for the isoleucine-derived α-keto-β-methylvaleric acid, followed by α-ketoisocaproate and α-ketoisovalerate. The enzyme's high affinity toward branched-chain α-keto acids allows it to function as the primer donating system for branched-chain fatty acid synthetase.
== Clinical significance == Several studies resulting in an initial information search on C3orf52 focused on the likely involvement of this gene in lipase H-mediated lysophosphatidic acid biosynthesis, a step in hair-follicle formation. Evidence shows that decreased expression of C3orf52 has been linked to localized autosomal recessive hypotrichosis, a condition resulting in the absence of hair. There were three relevant single-nucleotide polymorphisms found with clinical significance linked to hypotrichosis 15 (rs764787339, rs2472299130, rs545208237) (Table 2). Apart from articles on the involvement of C3orf52 in hair loss, PubMed and Google Scholar provided a couple of other potential linkages between this gene and diseases, specifically a variety of cancers. One of the more eye-catching articles found associations of this gene in the development of multifocal and multicentric breast cancer, and is looking into it as a current marker for distinguishing multifocal and multicentric breast cancer from unifocal breast cancers. Another study proposes looking at C3orf52 as a potential marker as a prognosis gene of cancer in a study looking at DNA copy number variations, which are common in cancer cells. Additionally, C3orf52 is linked to be downregulated in clear-cell renal cell carcinoma, and its reduced expression was linked to later disease stage and poorer overall survival of clear-cell renal cell carcinoma patients.
=== Fizzers === Fizzers are rolled-up tablet candies that fizz and dissolve when put into soda. They are similar to the American candy Smarties (called Rockets in Canada). Swizzels Matlow has also released a line of Giant Fizzers.
Sources: en.wikipedia.org
== DHEA in regards to aging == DHEA levels peak in early adulthood and gradually decline with age. By supplementing with DHEA, some individuals aim to restore hormone levels, potentially improving energy levels, mood, and libido. DHEA can help improve bone density as it is related to androgens which is important for bone health. DHEA controls the production of osteoblasts and insulin like growth factor 1 (IGF-1) expression which strengthens bone growth through metabolites. This helps delay the risk of osteoporosis in early adults.
==== Molecular interactions ==== As MALS can provide molar mass and size of molecules, it permits study into protein-protein binding, oligomerization and the kinetics of self-assembly, association and dissociation. By comparing the molar mass of a sample to its concentration, one can determine the binding affinity and stoichiometry of interacting molecules.
In May–June 1897, Thomson investigated whether or not the rays could be deflected by an electric field. Previous experimenters had failed to observe this, but Thomson believed their experiments were flawed because their tubes contained too much gas. Thomson constructed a Crookes tube with a better vacuum. At the start of the tube was the cathode from which the rays projected. The rays were sharpened to a beam by two metal slits – the first of these slits doubled as the anode, the second was connected to the earth. The beam then passed between two parallel aluminium plates, which produced an electric field between them when they were connected to a battery. The end of the tube was a large sphere where the beam would impact on the glass, created a glowing patch. Thomson pasted a scale to the surface of this sphere to measure the deflection of the beam. Any electron beam would collide with some residual gas atoms within the Crookes tube, thereby ionizing them and producing electrons and ions in the tube (space charge); in previous experiments this space charge electrically screened the externally applied electric field. However, in Thomson's Crookes tube the density of residual atoms was so low that the space charge from the electrons and ions was insufficient to electrically screen the externally applied electric field, which permitted Thomson to successfully observe electrical deflection.
== Clinical development == The drug was under development by Roche for treatment of schizophrenia and reached phase 3 clinical trials for this indication by 2019. The phase 2 results of RO5263397 do not appear to have been disclosed as of this date. However, some findings from one clinical study were published in 2015.
=== Dietary === In the United States, many people's diets are excessively high in calories, often due to fast food and sugary beverages. Individuals with obesity may consume more calories before feeling full, experience hunger more quickly, or eat in response to stress or anxiety. Per the USDA's Dietary Guidelines for Americans, 2020-2025, most Americans do not follow a healthy dietary pattern. Few individuals being tested for nutrient levels would be able to meet them without the use of fortification or enrichment. Americans eat an abundance of fast food. 36.6% of adults consume fast food on a given day and 2 out of 3 people consume fast food at least once a week. While the negative effects of fast food, such as lack of nutritional value and high amounts of calories, are widely known, fast food remains popular for its convenience, specifically because it is time-efficient and cheap. Quantity of food consumption plays an important role as well. A study shows a significant increase in food portion sizes of marketplace products since the 1970s that exceed the federal standards for dietary guidance. Reasons for this increase include the expansion of the food industry since the seventies, marketing strategies, and customer demand. Extreme differences in portion sizes between the same menu items of the same franchises have also been observed. In some instances, American food portion sizes are as much as double the size of their British counterparts.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.